This company develops organ-on-chip devices and assays for drug discovery and diagnostics. They provide products like chip devices for invasion and chemotaxis, alongside CRO services for assessing cell-cell interactions in 3D cell culture using their chip, enhanced by AI-based image analysis for quantitative assessment.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional preclinical testing methods often fail to accurately replicate the complex biological environments found in vivo, leading to inaccurate predictions of drug efficacy and toxicity. Conventional 2D cell cultures lack the cell-cell interactions and 3D architecture necessary for realistic modeling of tissue and organ functions. This can result in costly late-stage drug failures and delays in bringing new therapies to market.
Solution
Initio Cell offers organ-on-chip solutions that provide a more biologically relevant platform for preclinical drug development and research. Their DR-Chip platform enables researchers to conduct comprehensive studies with fewer experiments, accelerating the testing process and reducing costs. By simulating in vivo conditions, the DR-Chip delivers more accurate data on toxicology, efficacy, and PKPD, improving the predictability of preclinical results. Initio Cell's CRO services leverage these organ-on-chip devices, offering customizable assays and AI-based image analysis for quantitative assessment of cell behavior and drug responses. The platform supports various applications, including toxicology studies with physiologically relevant units (mg/kg), cardiovascular response testing, and cancer cell invasion studies.
Target Audience
The primary target audience includes pharmaceutical companies, biotech firms, and academic researchers involved in preclinical drug discovery and development, as well as those studying cell-cell interactions and metastatic potential.
Features
- DR-Chip platform for simulating in vivo conditions with 3D cell cultures
- Customizable assays for toxicology, efficacy, PKPD, and cell-cell interaction studies
- AI-based image analysis for quantitative assessment of results
- Capability to assess multiple doses across different cell types simultaneously
- Differential flow capabilities for simulating cardiovascular system behavior
- IC-Chip for determining invasion and chemotaxis in specific organ microenvironments
- DDI-Chip for testing autocrine and paracrine interactions and biological/chemical gradients
- Ability to create microenvironments of various tissues, including tumor, lung, gut, skin, brain, and vasculature